Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Selective molecular and network architecture features underlie brain cortical atrophy in dementia with Lewy bodies.

Journal of biomedical science·2026
Same author

The utility of a composite endpoint for tracking disease progression in Lewy body dementia.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Cerebrospinal fluid orexin testing in Australians with narcolepsy type 1.

Internal medicine journal·2026
Same author

Essential genetic testing in movement disorders - results from a Delphi study.

Parkinsonism & related disorders·2026
Same author

Reduced serum interleukin-2 associates with higher motor severity and along with CD4 T cell alterations may be an early event in isolated REM Sleep Behaviour Disorder.

Brain, behavior, & immunity - health·2026
Same author

The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network.

European journal of nuclear medicine and molecular imaging·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Joe Pm Kane1, Brad F Boeve2, Elie Matar3

  • 1Queen's University Belfast, Belfast, Northern Ireland, United Kingdom.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

Se está desarrollando una nueva Escala de Calificación de Dominios de la Demencia con Cuerpos de Lewy (LBD-DRS) para abordar la necesidad crítica de medidas de resultado específicas de LBD en ensayos clínicos. Esta escala tiene como objetivo mejorar el desarrollo de fármacos y la armonización de datos para la investigación de la Demencia con Cuerpos de Lewy.

Palabras clave:
Demencia con Cuerpos de LewyDesarrollo de fármacosEnsayos clínicosEscalas de calificaciónMedidas de resultadoArmonización de datos

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

Área de la Ciencia:

  • Neurología
  • Ensayos Clínicos
  • Investigación sobre Demencia

Sus antecedentes:

  • Los ensayos actuales de Demencia con Cuerpos de Lewy (LBD) utilizan escalas diseñadas para la enfermedad de Alzheimer y la enfermedad de Parkinson, lo que representa una necesidad crítica insatisfecha.
  • La heterogeneidad en el diseño de ensayos y las medidas de resultado dificulta la síntesis de evidencia y la armonización de datos en la investigación de LBD.
  • El desarrollo de una escala específica para LBD es crucial para avanzar en las carteras de desarrollo de fármacos.

Objetivo del estudio:

  • Describir el desarrollo de la Escala de Calificación de Dominios de la Demencia con Cuerpos de Lewy (LBD-DRS).
  • Proponer una hoja de ruta para la adopción y validación de la LBD-DRS.
  • Abordar la necesidad crítica insatisfecha de medidas de resultado específicas de LBD en ensayos clínicos.

Principales métodos:

  • Se empleó un proceso de encuesta Delphi de tres rondas, que involucró a investigadores y clínicos de LBD.
  • El consenso se definió como acuerdo entre el ≥75% de los encuestados sobre las declaraciones de la encuesta.
  • El proceso se centró en establecer un consenso sobre el marco conceptual y el contenido preliminar de la LBD-DRS.

Principales resultados:

  • Se logró un consenso sobre la necesidad de una escala específica para LBD, particularmente para LBD en etapa temprana.
  • Se ha desarrollado una tercera versión de la LBD-DRS basada en los comentarios de dos versiones anteriores.
  • Se ha adoptado un enfoque de puntuación inclusivo para los síntomas, reconociendo la necesidad de futuras iteraciones con datos de campo.

Conclusiones:

  • El desarrollo adicional de la LBD-DRS implicará la consulta con diversas partes interesadas, incluidas personas con LBD y sus cuidadores.
  • La participación con los organismos reguladores y la industria farmacéutica informará las fases de desarrollo posteriores.
  • Se buscarán estudios de validación después de una consulta integral con las partes interesadas y la participación regulatoria.